The aim of this study was to compare clinical outcomes in relation to the duration of triple antithrombotic therapy in patients with indications for oral anticoagulation undergoing coronary angioplasty. The optimal period for the prescription of these three drugs has not been studied. Between 2009 and 2013, 8772 consecutive patients undergoing coronary angioplasty were included...
This study examines predictors and outcomes associated with the prescription of beta-blockers at discharge after a successful coronary angioplasty in patients with stable chronic angina WITHOUT prior history of acute myocardial infarction or heart failure. The benefit of beta-blockers in patients with acute myocardial infarction or systolic heart failure is well documented. However, their...
Original Title: Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. Reference: Kinstner CM et al. J Am Coll Cardiol Intv. 2016;9:1386-1392. Patients with symptomatic femoropopliteal in-stent restenosis (ISR) have better patency at one year if treated with drug eluting...
Original Title: Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial. Reference: Marlon I. Spreen et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002376. The treatment of infrapopliteal lesions in patients with critical limb ischemia is limited by the high rates of restenosis. The most frequent course of treatment is...
Original Title: Sustained Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. 24-Month Results of IN.PACT SFA. Reference: John R. Laird et al. J Am CollCardiol. 2015 [Epub ahead of print]. The IN.PACT SFA studies and follows up patients treated with IN.PACT Admiral DCB (Medtronic®) for superficial femoral artery (SFA) and popliteal artery disease....
There are many doubts about the benefit of manual thromboaspiration, not only in terms of improvement of the clinical end point but also the potential risk of stroke. The TOTAL (n = 10732) was a randomized study of routine manual thrombectomy versus angioplasty only in the context of ST segment elevation acute myocardial infarction and...
The main predictor of adverse outcomes (thrombosis and restenosis) after implantation of a stent is the degree of expansion according to published studies using coronary intravascular ultrasound (IVUS). It is unknown whether optical coherence tomography (OCT), in this sense, provides similar information as the IVUS. The aim of this study was to compare the degree...
This work included 18144 patients from 39 countries that were admitted pursuing an acute coronary syndrome (with or without ST segment elevation) randomized 1: 1 to receive the combination of simvastatin 40 mg / ezetimibe 10 mg (n = 9067) or simvastatin 40 mg alone (n = 9077). Of the total, 88% received a coronary...
The aim of this study was to assess treatment with the new anticoagulant Pegnivacogin and its specific antidote Anivamersen compared with bivalirudin in patients undergoing coronary angioplasty. The Pegnivacogin has an affinity for factor IXa with a longer shelf life to 24 hours and Anivamersen only has an affinity for Pegnivacogin. The combination of these...
The platelet P2Y12 receptor antagonist ticagrelor is shown to reduce the incidence of cardiovascular events when administered in hospital admission to patients suffering an ST-segment elevation acute myocardial infarction. Pre-hospital management that could improve coronary reperfusion and events like death or stent thrombosis was not studied. 1862 patients were included suffering ST-segment elevation acute myocardial...